Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Megace ES

×

Overview

What is Megace ES?

®

                                                                                                                                                          

®

®



What does Megace ES look like?



What are the available doses of Megace ES?

Sorry No records found.

What should I talk to my health care provider before I take Megace ES?

Sorry No records found

How should I use Megace ES?

®

Please refer to the table below for correct dosing and administration

®


What interacts with Megace ES?

Sorry No Records found


What are the warnings of Megace ES?

Sorry No Records found


What are the precautions of Megace ES?

Sorry No Records found


What are the side effects of Megace ES?

Sorry No records found


What should I look out for while using Megace ES?


What might happen if I take too much Megace ES?


How should I store and handle Megace ES?

Store bottles of 1000 SINGULAIR 5-mg chewable tablets and 8000 SINGULAIR 10-mg film-coated tablets at 25°C (77°F), excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Protect from moisture and light. Store in original container. When product container is subdivided, repackage into a well-closed, light resistant container. ®®Health Hazard DataWARNINGSADVERSE REACTIONSAR PHARMACEUTICAL COMPANIES, INC.®®®Health Hazard DataWARNINGSADVERSE REACTIONSAR PHARMACEUTICAL COMPANIES, INC.®®®Health Hazard DataWARNINGSADVERSE REACTIONSAR PHARMACEUTICAL COMPANIES, INC.®®®Health Hazard DataWARNINGSADVERSE REACTIONSAR PHARMACEUTICAL COMPANIES, INC.®®®Health Hazard DataWARNINGSADVERSE REACTIONSAR PHARMACEUTICAL COMPANIES, INC.®®®Health Hazard DataWARNINGSADVERSE REACTIONSAR PHARMACEUTICAL COMPANIES, INC.®®®Health Hazard DataWARNINGSADVERSE REACTIONSAR PHARMACEUTICAL COMPANIES, INC.®


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

®

®

ADVERSE

REACTIONS

                                                                     

                                                                         

                                                                   

Non-Clinical Toxicology
Catecholamine-depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor should therefore be closely observed for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.

Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone are likely to increase metoprolol concentration. In healthy subjects with CYP2D6 extensive metabolizer phenotype, coadministration of quinidine 100 mg and immediate release metoprolol 200 mg tripled the concentration of S-metoprolol and doubled the metoprolol elimination half-life. In four patients with cardiovascular disease, coadministration of propafenone 150 mg t.i.d. with immediate-release metoprolol 50 mg t.i.d. resulted in two- to five-fold increases in the steady-state concentration of metoprolol. These increases in plasma concentration would decrease the cardioselectivity of metoprolol.

Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Beta-blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine. If replacing clonidine by beta-blocker therapy, the introduction of beta-blockers should be delayed for several days after clonidine administration has stopped.

PRECAUTIONS:

Impairment of Fertility

PRECAUTIONS: Carcinogenesis, Mutagenesis, and Impairment of Fertility

®

Clinical Adverse Events

®

WARNINGS

PRECAUTIONS

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).